Search Results - "Gynecologic oncology"

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019 by Gu, Baoxia, Shang, Xiaogai, Yan, Mengqing, Li, Xiao, Wang, Wei, Wang, Qi, Zhang, Cuilian

“…Endometrial cancer (EC) is a commonly diagnosed cancer in women. A comprehensive knowledge of its epidemiological features is essential for understanding the…”
Get full text

Validation of the 2018 FIGO cervical cancer staging system by Matsuo, Koji, Machida, Hiroko, Mandelbaum, Rachel S., Konishi, Ikuo, Mikami, Mikio

“…To validate the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer, with a particular focus on stage…”
Get full text

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028 by Varga, Andrea, Piha-Paul, Sarina, Ott, Patrick A., Mehnert, Janice M., Berton-Rigaud, Dominique, Morosky, Anne, Yang, Ping, Ruman, Jane, Matei, Daniela

“…To evaluate safety, tolerability, and antitumor activity of pembrolizumab monotherapy in patients with programmed death ligand 1 (PD-L1)–expressing advanced…”
Get full text

Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations by Holloway, Robert W, Abu-Rustum, Nadeem R, Backes, Floor J, Boggess, John F, Gotlieb, Walter H, Jeffrey Lowery, W, Rossi, Emma C, Tanner, Edward J, Wolsky, Rebecca J

“…Abstract The emphasis in contemporary medical oncology has been “precision” or “personalized” medicine, terms that imply a strategy to improve efficacy through…”
Get full text

HPV vaccines – A review of the first decade by Harper, Diane M, DeMars, Leslie R

“…Abstract Pre-adolescent girls (9–15 years) have the option of receiving a two dose HPV vaccine series at either a six month or one year interval to provide…”
Get full text

Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis by Bisch, S.P., Jago, C.A., Kalogera, E., Ganshorn, H., Meyer, L.A., Ramirez, P.T., Dowdy, S.C., Nelson, G.

“…To assess the benefit of Enhanced Recovery After Surgery (ERAS) on length of stay (LOS), postoperative complications, 30-day readmission, and cost in…”
Get full text

Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part I by Nelson, G, Altman, A.D, Nick, A, Meyer, L.A, Ramirez, P.T, Achtari, C, Antrobus, J, Huang, J, Scott, M, Wijk, L, Acheson, N, Ljungqvist, O, Dowdy, S.C

“…Highlights • We provide evidence supporting pre- and intra-operative management of patients undergoing gynecologic/oncology surgery. • This guideline will help…”
Get full text

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 by Oza, Amit M., Tinker, Anna V., Oaknin, Ana, Shapira-Frommer, Ronnie, McNeish, Iain A., Swisher, Elizabeth M., Ray-Coquard, Isabelle, Bell-McGuinn, Katherine, Coleman, Robert L., O'Malley, David M., Leary, Alexandra, Chen, Lee-may, Provencher, Diane, Ma, Ling, Brenton, James D., Konecny, Gottfried E., Castro, Cesar M., Giordano, Heidi, Maloney, Lara, Goble, Sandra, Lin, Kevin K., Sun, James, Raponi, Mitch, Rolfe, Lindsey, Kristeleit, Rebecca S.

“…•Oral rucaparib (600mg BID) is efficacious in advanced relapsed ovarian carcinoma.•The objective response rate was 54% in BRCA1/2-mutated ovarian…”
Get full text

Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part II by Nelson, G, Altman, A.D, Nick, A, Meyer, L.A, Ramirez, P.T, Achtari, C, Antrobus, J, Huang, J, Scott, M, Wijk, L, Acheson, N, Ljungqvist, O, Dowdy, S.C

“…Highlights • We provide evidence supporting postoperative management of patients undergoing gynecologic/oncology surgery. • This guideline will help integrate…”
Get full text

An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations by Salani, Ritu, Khanna, Namita, Frimer, Marina, Bristow, Robert E, Chen, Lee-may

“…Abstract Gynecologic cancers account for ~ 12% of all new cancer cases in women and ~ 15% of all female cancer survivors. Current and continued advances within…”
Get full text

Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test by Wright, Thomas C, Stoler, Mark H, Behrens, Catherine M, Sharma, Abha, Zhang, Guili, Wright, Teresa L

“…Abstract Objectives ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer in women ≥ 25 years. This reports the 3-year end-of-study…”
Get full text

Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline by Wright, Alexi A, Bohlke, Kari, Armstrong, Deborah K, Bookman, Michael A, Cliby, William A, Coleman, Robert L, Dizon, Don S, Kash, Joseph J, Meyer, Larissa A, Moore, Kathleen N, Olawaiye, Alexander B, Oldham, Jessica, Salani, Ritu, Sparacio, Dee, Tew, William P, Vergote, Ignace, Edelson, Mitchell I

“…Abstract Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV…”
Get full text

TCGA molecular groups of endometrial cancer: Pooled data about prognosis by Raffone, Antonio, Travaglino, Antonio, Mascolo, Massimo, Carbone, Luigi, Guida, Maurizio, Insabato, Luigi, Zullo, Fulvio

“…AbstractBackgroundAfter The Cancer Genome Atlas (TCGA) findings, four novel prognostic groups may direct the management of endometrial cancer (EC):…”
Get full text

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer by Webb, John R, Milne, Katy, Kroeger, David R, Nelson, Brad H

“…Abstract Objective As a negative regulator of T cells, Programmed Death Ligand 1 (PD-L1) is both an indicator and inhibitor of anti -tumor immune responses,…”
Get full text

Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance by Huh, Warner K, Ault, Kevin A, Chelmow, David, Davey, Diane D, Goulart, Robert A, Garcia, Francisco A.R, Kinney, Walter K, Massad, L. Stewart, Mayeaux, Edward J, Saslow, Debbie, Schiffman, Mark, Wentzensen, Nicolas, Lawson, Herschel W, Einstein, Mark H

“…Abstract In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology…”
Get full text

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) by Santin, Alessandro D., Deng, Wei, Frumovitz, Michael, Buza, Natalia, Bellone, Stefania, Huh, Warner, Khleif, Samir, Lankes, Heather A., Ratner, Elena S., O'Cearbhaill, Roisin E., Jazaeri, Amir A., Birrer, Michael

“…Patients with persistent/recurrent cervical cancer following platinum-based chemotherapy have limited therapeutic options. The Gynecologic-Oncology-Group…”
Get full text

Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis by Yuan, Xia, Zhang, Jing, Li, Dan, Mao, Ye, Mo, Fei, Du, Wei, Ma, Xuelei

“…The role of tumor-associated macrophages (TAMs) in tumor microenvironment remains controversial due to the two different polarized subsets of TAMs. Here, we…”
Get full text

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer by Mabuchi, Seiji, Kuroda, Hiromasa, Takahashi, Ryoko, Sasano, Tomoyuki

“…Abstract The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway plays a critical role in the malignant transformation of…”
Get full text

METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition by Hua, Wenfeng, Zhao, Yuan, Jin, Xiaohan, Yu, Danyang, He, Jing, Xie, Dan, Duan, Ping

“…As the most prevalent internal modification in mammalian messenger RNA, N6‑methyladenosine (m6A) plays an important role in posttranscriptional gene…”
Get full text

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial by Wortman, B.G., Bosse, T., Nout, R.A., Lutgens, L.C.H.W., van der Steen-Banasik, E.M., Westerveld, H., van den Berg, H., Slot, A., De Winter, K.A.J., Verhoeven-Adema, K.W., Smit, V.T.H.B.M., Creutzberg, C.L.

“…The Post-Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-4a trial is a randomized trial for women with high-intermediate risk endometrial cancer…”
Get full text